Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Auteurs

E. Vrdoljak, N. Marschner, C. Zielinski, J. Gligorov, J. Cortes, F. Puglisi, M. Aapro, L. Fallowfield, A. Fontana, M. Inbar, Z. Kahan, A. Welt, C. Lévy, E. Brain, X. Pivot, C. Putzu, A. González Martín, S. de Ducla, V. Easton, G. von Minckwitz